Literature DB >> 31737416

How to Manage Disfiguring Scars in Involuted Infantile Hemangioma.

Shunsuke Yuzuriha1, Fumio Nagai1, Masahiko Noguchi2.   

Abstract

Objective: No active treatment is required in the majority of cases of infantile hemangioma (IH), while they proliferate and involute without sequelae. However, ulceration, bleeding, or destruction/obstruction of important structures may occur in 10% of cases during the proliferating phase. These lesions lead to a disfigured appearance with redundant skin, fibrofatty residuum, protruding surface, drooping, and scarring. This study focused on prevention and management of disfiguring scars in involuted IH. Approach: A retrospective photography and chart review were performed for patients with IH who visited our hospital (Shinshu University Hospital).
Results: The study population consisted of 107 patients with IH. The lesions were located on the head and neck (59.8%), trunk (27.1%), upper limb (7.5%), or lower limb (5.6%). Twenty-four patients (22.4%) underwent surgical excision of the disfigured lesion after involution. The percentage of surgical interventions was highest for lesions in the head and neck area (28.9%) compared with other regions. The fibrofatty tissue and redundant skin after involution of each lesion were partly resected and sutured. All suture lines were finally set on the wrinkle line or the anatomical borderline. Innovation: Although total excision of the lesion was impossible in some cases, a natural surface contour was obtained. The operative scar was not visible in the residual damaged skin after involution.
Conclusion: Effective preventive therapies during the proliferating phase are required to avoid tissue damage due to hyperexpansion of the surrounding tissue and surface breakdown to present excellent cosmetic results in patients with IH. Copyright 2019, Mary Ann Liebert, Inc., publishers.

Entities:  

Keywords:  disfigure; infantile hemangioma; involution; scar; surgical intervention; ulceration

Year:  2019        PMID: 31737416      PMCID: PMC6855289          DOI: 10.1089/wound.2018.0847

Source DB:  PubMed          Journal:  Adv Wound Care (New Rochelle)        ISSN: 2162-1918            Impact factor:   4.730


  39 in total

1.  A miniunit approach to lip reconstruction.

Authors:  Y Iwahira; Y Maruyama; M Yoshitake
Journal:  Plast Reconstr Surg       Date:  1994-05       Impact factor: 4.730

2.  Imiquimod 5% cream versus timolol 0.5% ophthalmic solution for treating superficial proliferating infantile haemangiomas: a retrospective study.

Authors:  Y Qiu; G Ma; J Yang; X Hu; H Chen; Y Jin; X Lin
Journal:  Clin Exp Dermatol       Date:  2013-04-30       Impact factor: 3.470

3.  A randomized, controlled trial of oral propranolol in infantile hemangioma.

Authors:  Christine Léauté-Labrèze; Peter Hoeger; Juliette Mazereeuw-Hautier; Laurent Guibaud; Eulalia Baselga; Gintas Posiunas; Roderic J Phillips; Hector Caceres; Juan Carlos Lopez Gutierrez; Rosalia Ballona; Sheila Fallon Friedlander; Julie Powell; Danuta Perek; Brandie Metz; Sebastien Barbarot; Annabel Maruani; Zsuzsanna Zsofia Szalai; Alfons Krol; Olivia Boccara; Regina Foelster-Holst; Maria Isabel Febrer Bosch; John Su; Hana Buckova; Antonio Torrelo; Frederic Cambazard; Rainer Grantzow; Orli Wargon; Dariusz Wyrzykowski; Jochen Roessler; Jose Bernabeu-Wittel; Adriana M Valencia; Przemyslaw Przewratil; Sharon Glick; Elena Pope; Nicholas Birchall; Latanya Benjamin; Anthony J Mancini; Pierre Vabres; Pierre Souteyrand; Ilona J Frieden; Charles I Berul; Cyrus R Mehta; Sorilla Prey; Franck Boralevi; Caroline C Morgan; Stephane Heritier; Alain Delarue; Jean-Jacques Voisard
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

4.  Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics.

Authors:  Anita N Haggstrom; Beth A Drolet; Eulalia Baselga; Sarah L Chamlin; Maria C Garzon; Kimberly A Horii; Anne W Lucky; Anthony J Mancini; Denise W Metry; Brandon Newell; Amy J Nopper; Ilona J Frieden
Journal:  J Pediatr       Date:  2007-03       Impact factor: 4.406

5.  Unilateral cleft lip repair: an anatomical subunit approximation technique.

Authors:  David M Fisher
Journal:  Plast Reconstr Surg       Date:  2005-07       Impact factor: 4.730

6.  Aesthetic restoration of one-half the upper lip.

Authors:  G C Burget; F J Menick
Journal:  Plast Reconstr Surg       Date:  1986-11       Impact factor: 4.730

7.  Growth characteristics of infantile hemangiomas: implications for management.

Authors:  Linda C Chang; Anita N Haggstrom; Beth A Drolet; Eulalia Baselga; Sarah L Chamlin; Maria C Garzon; Kimberly A Horii; Anne W Lucky; Anthony J Mancini; Denise W Metry; Amy J Nopper; Ilona J Frieden
Journal:  Pediatrics       Date:  2008-08       Impact factor: 7.124

8.  Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics.

Authors:  J B Mulliken; J Glowacki
Journal:  Plast Reconstr Surg       Date:  1982-03       Impact factor: 4.730

9.  Multicenter prospective study of ulcerated hemangiomas.

Authors:  Sarah L Chamlin; Anita N Haggstrom; Beth A Drolet; Eulalia Baselga; Ilona J Frieden; Maria C Garzon; Kimberly A Horii; Anne W Lucky; Denise W Metry; Brandon Newell; Amy Jo Nopper; Anthony J Mancini
Journal:  J Pediatr       Date:  2007-08-24       Impact factor: 4.406

Review 10.  Management of haemangiomas of infancy: a retrospective analysis and a treatment protocol.

Authors:  Constantijn G Bauland; Jeroen M Smit; Rein Ketelaars; Paul N M A Rieu; Paul H M Spauwen
Journal:  Scand J Plast Reconstr Surg Hand Surg       Date:  2008
View more
  2 in total

1.  The effectiveness of oral propranolol for infantile hemangioma on the head and neck region: A case series.

Authors:  Prasetyanugraheni Kreshanti; Nandya Titania Putri; Valencia Jane Martin; Chaula Luthfia Sukasah
Journal:  Int J Surg Case Rep       Date:  2021-06-19

2.  Propranolol vs. steroids in the treatment of infantile hemangiomas: A meta-analysis.

Authors:  Yiting You; Yadong Li; Yiting Xiao; Jinsong Zhang
Journal:  Mol Clin Oncol       Date:  2021-06-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.